Your 510(k) specialist is placed by Tuesday. Your pipeline is placed by one hiring manager's notice period.

Your firm places the people who keep drug and device companies on the right side of FDA, EMA, and global health authority requirements. The work is exacting, the candidates are scarce, and your reputation in the industry is what earns you repeat engagement. But a referral-only pipeline has a ceiling. At some point, the same directors and VPs who recommend you have no new openings to fill, and your growth stalls.

The Buyer You Need to Reach

The person who buys regulatory affairs staffing is not a generalist HR manager running a req through an ATS. They are a VP of Regulatory Affairs, a Quality Assurance director, or a Chief Compliance Officer who has a specific gap: a 510(k) submission due in fourteen weeks, a Pre-IND meeting with no experienced CMC lead, a post-approval CMC change management queue that internal headcount cannot clear. They need someone who has done the exact work before, who knows the FDA's current thinking on analytical comparability, who can walk into a Type A meeting and not embarrass the sponsor.

These buyers do not respond to generic staffing pitches. They receive dozens of them weekly from contingency firms promising "top regulatory talent" with no evidence the recruiter can distinguish a CMC section from a clinical summary. What they do respond to is specificity: a letter that names the submission type, the therapeutic area, the regulatory pathway, and the exact profile of the candidate who has done it before.

Your buyers also hire in bursts. A Phase III company preparing for BLA submission may need three regulatory CMC consultants for eight months, then nothing for two years. A mid-size device firm may staff up for a PMA panel, then shed headcount. The timing matters more than the relationship. Being in correspondence when the gap opens is the entire game.

Why Referrals Stop Scaling

A referral from a satisfied VP Regulatory Affairs is the best lead you will ever get. It closes fast, the scope is usually clear, and the buyer already trusts your judgment. The problem is arithmetic. A VP who moves every three years can refer you twice, maybe three times. A director who stays in role for five years refers you once. The total addressable pool of people who have both hired you and know someone with an active need is small, and it does not grow with your revenue target.

Worse, referrals cluster in the same company size and stage. The VP who hired you at a mid-cap biotech knows other mid-cap biotech VPs. They do not know the regulatory affairs leader at a European device manufacturer entering the US market, or the compliance officer at a generics firm building a new ANDA program. Your referral network reinforces the segment you already serve and leaves adjacent markets untouched.

Outbound correspondence solves this by reaching the buyer directly, at the moment of need, with no intermediary. The letter or email does not require a mutual connection. It requires only that you identify the right person, understand their program, and speak in the language of their work.

The Three Channels, Sequenced

ROI Wire runs Email Correspondence, Direct Mail, and Retargeting as a single program, with phone follow-up timed to the sequence. Each channel does a different job in the regulatory affairs staffing sale.

Direct Mail Opens the Door

A physical letter to a VP Regulatory Affairs at a clinical-stage oncology company lands differently than an email. It signals that your firm has identified this specific program, this specific gap, and this specific person. The letter does not pitch "staffing services." It identifies a situation: the company's recent IND filing, the upcoming end-of-Phase II meeting, the likely need for a CMC regulatory lead who has shepherded an oncology BLA through in the last four years.

The letter names the candidate profile without naming any individual. It describes the experience threshold: twelve years in CMC regulatory, direct involvement in two or more BLAs, current knowledge of FDA's expectations for potency assay validation in cell therapy. It closes with a concrete next step: a fifteen-minute conversation to confirm whether this profile matches the program's timeline.

Direct Mail is especially effective for senior buyers who do not monitor their LinkedIn messages and who have trained themselves to ignore recruiter email. A letter on their desk, referencing a public regulatory milestone, is harder to dismiss.

Email Correspondence Builds the Case

The email sequence that follows the letter does not repeat the same pitch. Each message adds a specific element: a note on the FDA's recent draft guidance relevant to the company's therapeutic area, a brief observation on a competitor's approved labeling that suggests regulatory strategy experience, a direct question about the timeline for their anticipated pre-BLA meeting.

The emails are short, usually under 150 words. They assume the buyer is busy and knows their own needs better than you do. They do not use staffing industry jargon like "talent acquisition" or "workforce solutions." They speak the buyer's language: submission timelines, CMC strategy, health authority interactions, regulatory intelligence.

Email Correspondence also allows for precise timing. If a company announces a Phase III readout, a partnership with a CDMO, or a new regulatory hire, the sequence can reference that event within days. This responsiveness is impossible with referral-dependent pipeline development.

Retargeting Reinforces the Memory

The Retargeting program places digital display and social placements to the named buyer profiles who have received the mail and email. A VP Regulatory Affairs who read your letter but did not respond sees a discreet placement during their normal industry news reading. The creative does not sell. It reminds: your firm identified their program, named the gap, and offered a specific profile.

Retargeting is not a replacement for the correspondence. It is a frequency layer that keeps your firm present during the long evaluation cycles typical of regulatory staffing decisions. A buyer may need four to six weeks to secure budget approval for a contract regulatory role, or to confirm that internal headcount cannot be reallocated. Retargeting ensures your firm is not forgotten during that gap.

Phone Follow-Up Completes the Loop

The phone call, when it comes, references the letter by date and the emails by subject line. The operator does not open with a pitch. They open with confirmation: "You received our letter on the CMC lead for the BLA program. I am calling to see whether the timeline we identified matches what you are seeing internally."

This is not an uninvited call. The buyer has already been in correspondence. They know the firm, the specific program referenced, and the candidate profile offered. The call's purpose is to move from awareness to a scheduled conversation about the engagement terms: contract duration, hourly rate structure, your firm's placement guarantee, and the candidate vetting process.

What the Correspondence Actually Says

The copy ROI Wire produces for regulatory affairs staffing firms is written in the voice of a practitioner, not a recruiter. It does not lead with "we have a deep bench of regulatory talent." It leads with the buyer's situation.

A letter to a VP Regulatory Affairs at a gene therapy company might open with the company's recent IND acceptance and the known challenge of CMC regulatory strategy for AAV manufacturing scale-up. It would name the specific profile: a regulatory CMC lead who has managed FDA interactions for a lentiviral or AAV program, who understands the CMC considerations for Phase I/II to Phase III transition, and who is available for an eighteen-month contract engagement.

The copy does not promise to "find" this person. It states that your firm identifies, qualifies, and places such profiles regularly, and that you are currently in conversation with candidates who match this description. The implication is that your network is active and current, not a database of outdated resumes.

The copy also addresses the buyer's risk. Regulatory affairs staffing failures are expensive: a CMC consultant who misunderstands FDA expectations can delay a submission by months. The correspondence notes your firm's vetting process: direct interview by a former regulatory affairs professional, reference verification with prior hiring managers, and a replacement guarantee if the placement does not perform within the first thirty days.

How ROI Wire Structures the Engagement

Engagements vary based on your firm's size, typical placement value, and growth target. Some regulatory affairs staffing firms run on a retainer model: a monthly fee for outbound program operation, with the firm retaining all placement revenue. Others prefer a revenue share: the firm covers advertising spend and infrastructure cost, and ROI Wire takes a percentage of the revenue from placements that originated in the correspondence program.

Revenue share is not always the right fit. If your average placement cycle is long, or if your firm has thin margins on contract staffing, a retainer may make more sense. ROI Wire does not publish a single price or percentage. The structure is discussed after understanding your firm's economics, your typical buyer profile, and the size of the addressable market you have not yet reached.

What does not vary is the work. ROI Wire builds the contact list of VP Regulatory Affairs, QA directors, and compliance officers at the company stage and therapeutic area you specify. It writes the correspondence in your firm's voice, referencing the regulatory milestones and candidate profiles that matter to your buyers. It manages the sequencing, the retargeting placements, and the phone follow-up. Your firm handles the candidate sourcing, the client relationship, and the placement itself. ROI Wire does not touch candidates, resumes, or client confidential program information.

The Regulatory Context: Why This Matters

Regulatory affairs staffing sits at the intersection of high consequence and high scarcity. A missed FDA submission deadline can cost a company hundreds of millions in delayed revenue. A warning letter response requires regulatory expertise that the company may not have in-house. The candidates who can do this work are not browsing job boards. They are employed, often at competitors, and they move through professional networks and specialized recruiters.

The buyers know this. They do not expect to find a qualified CMC regulatory lead through a generalist staffing firm. They expect to find them through a firm that demonstrates specific knowledge of their program, their pathway, and their timeline. Outbound correspondence is the mechanism for demonstrating that knowledge before the buyer has ever spoken to you.

The regulatory environment also creates natural urgency windows. The FDA Reauthorization Act of 2022 (Public Law 117-180) and subsequent user fee program changes affect submission timelines. New draft guidance on topics like platform technology designation or CMC post-approval change management creates immediate need for specialized expertise. Correspondence that references these developments, accurately and specifically, signals that your firm is current in a way that generic staffing pitches are not.

Who This Is Not For

ROI Wire does not take on regulatory affairs staffing firms that are combative with buyers, unwilling to pay fairly for the program, or unable to describe their candidate profiles with specificity. If your firm places "regulatory people" generally, without distinguishing between CMC, clinical, and labeling strategy, the correspondence will not land. The copy requires real detail to be credible.

The program also does not work for firms that expect instant results. Regulatory affairs staffing sales cycles run eight to sixteen weeks from first contact to signed engagement. The correspondence program builds a pipeline over that horizon. If your firm needs placements this month to make payroll, this is not the right investment.

Finally, ROI Wire does not work with firms that blur the line between contract staffing and permanent placement without clear disclosure to buyers. The correspondence states the engagement type explicitly. If your firm switches models mid-conversation, the trust built in the correspondence is wasted.